多替阿巴拉米片的服用说明

The treatment plan is based on DTG, an integrase inhibitor, as the core drug, coupled with two backbone drugs, abacavir and lamivudine, and made into a single-tablet treatment for promotion, which has made great progress in the HAART treatment of core drugs. On August 27, 2014, Docelotabalamid tablets were approved by the FDA for marketing. On January 20, 2018, ViiV, a joint venture of GlaxoSmithKline, launched Inbec, the first complete antiviral treatment plan with dolutegravir (also known as DTG in English) as the core, officially launched in China. This is also the first complete single-pill compound treatment plan in the field of HIV treatment in China. Today let’s take a look at the instructions for taking Abalami Tablets.

For adults and adolescents, the recommended dose of Dolutegra is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

If the patient misses a dose of Inbec, and there is more than 4 hours before the next dose, the patient should take Inbec as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adults. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when administering the drug in this age group.

Patients whose creatinine clearance is less than 50 mL/min are not recommended to take doptabalamid tablets. Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of dolutea is not recommended unless deemed necessary. For patients with mild hepatic impairment, close monitoring is required, including monitoring of abacavir plasma levels when feasible.

The above is the content of the dosage instructions, I hope it can help you!